1. Summary of the included treatment comparisons.
| Trial | Year recruitment started | Intervention (platinum‐containing) | Control | Platinum agent | Same backbone? | Adjuvant or neoadjuvant | Hormone receptor IHC cut‐off |
| ADAPT‐TN | 2013 | Nab‐paclitaxel 125 mg/m2 + carboplatin AUC2 days 1 and 8 every 3 weeks for 4 cycles | Nab‐paclitaxel 125 mg/m2 + gemcitabine 1000 mg/m2 days 1 and 8 every 3 weeks for 4 cycles | Carboplatin AUC2 every week (days 1 and 8 every 21 days) | No | Neoadjuvant | < 1% |
| Ando 2014 | 2010 | Carboplatin AUC5 every 3 weeks for 4 cycles + paclitaxel 80 mg/m2 days 1, 8, 15 for 4 cycles, followed by 4 cycles of cyclophosphamide 500 mg/m2, epirubicin 100 mg/m2 and fluorouracil 500 mg/m2 every 3 weeks | Paclitaxel 80 mg/m2 days 1, 8, 15 for 4 cycles followed by 4 cycles of cyclophosphamide 500 mg/m2, epirubicin 100 mg/m2 and fluorouracil 500 mg/m2 every 3 weeks | Carboplatin AUC5 every 3 weeks | Yes | Neoadjuvant | < 10% |
| BrighTNess comparison 1 | 2014 | Paclitaxel 80 mg/m2 weekly + carboplatin AUC6 every 3 weeks for 12 weeks + veliparib 50 mg twice a day, followed by doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 2 or 3 weeks for 4 cycles | Paclitaxel 80 mg/m2 weekly for 12 weeks, followed by doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 2 or 3 weeks for 4 cycles | Carboplatin AUC6 every 3 weeks | Yes | Neoadjuvant | < 1% |
| BrighTNess comparison 2 | 2014 | Paclitaxel 80 mg/m2 weekly + carboplatin AUC6 every 3 weeks for 12 weeks, followed by doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 2 or 3 weeks for 4 cycles | Paclitaxel 80 mg/m2 weekly for 12 weeks, followed by doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 2 or 3 weeks for 4 cycles | Carboplatin AUC6 every 3 weeks | Yes | Neoadjuvant | < 1% |
| CALGB 40603 | 2009 | Paclitaxel 80 mg/m2 weekly + carboplatin AUC6 every 3 weeks for 12 weeks followed by doxorubicin 60 mg/m2 + cyclophosphamide 600 mg/m2 every 2 weeks for 4 cycles ± bevacizumab 10 mg/kg every 2 weeks for 9 cycles | Paclitaxel 80 mg/m2 weekly for 12 weeks followed by doxorubicin 60 mg/m2 + cyclophosphamide 600 mg/m2 every 2 weeks for 4 cycles ± bevacizumab 10 mg/kg every 2 weeks for 9 cycles | Carboplatin AUC6 every 3 weeks | Yes | Neoadjuvant | < 10% |
| GEICAM 2006‐03 | 2007 | Epirubicin 90 mg/m2 + cyclophosphamide 600 mg/m2 every 3 weeks for 4 cycles followed by docetaxel 75 mg/m2 + carboplatin AUC6 every 3 weeks for 4 cycles | Epirubicin 90 mg/m2 + cyclophosphamide 600 mg/m2 every 3 weeks for 4 cycles followed by docetaxel 75 mg/m2 every 3 weeks for 4 cycles | Carboplatin AUC6 every 3 weeks | Yes | Neoadjuvant | Not described |
| GeparOcto | 2014 | Paclitaxel 80 mg/m2 + non‐pegylated liposomal doxorubicin 20 mg/m2 + carboplatin AUC1.5 weekly for 18 weeks | Epirubicin 150 mg/m2 + paclitaxel 225 mg/m2 + cyclophosphamide 2000 mg/m2 every 2 weeks for 3 cycles | Carboplatin AUC1.5 every week | No | Neoadjuvant | < 1% |
| GeparOLA | 2016 | Paclitaxel 80 mg/m2 + carboplatin AUC2 weekly for 12 weeks followed by epirubicin 90 mg/m2 + cyclophosphamide 600 mg/m2 every 2 or 3 weeks for 4 cycles | Paclitaxel 80 mg/m2 weekly + olaparib 100 mg twice a day for 12 weeks followed by epirubicin 90 mg/m2 + cyclophosphamide 600 mg/m2 every 2 or 3 weeks for 4 cycles | Carboplatin AUC2 every week | No | Neoadjuvant | < 1% |
| GeparSixto | 2011 | Carboplatin AUC2 or 1.5 + paclitaxel 80 mg/m2 + non‐pegylated liposomal doxorubicin 20 mg/m2 + bevacizumab 15 mg/kg every 3 weeks for 18 weeks | Paclitaxel 80 mg/m2 + non‐pegylated liposomal doxorubicin 20 mg/m2 weekly + bevacizumab 15 mg/kg every 3 weeks for 18 weeks | Carboplatin AUC1.5 or 2 every week | Yes | Neoadjuvant | < 1% |
| Gigolaeva 2019 | NR | Doxorubicin 60 mg/m2 + cyclophosphamide 600 mg/m2 every 3 weeks for 4 cycles followed by carboplatin AUC2 weekly + eribulin 1.4 mg/m2 or paclitaxel 175 mg/m2 every 3 weeks for 12 weeks | Doxorubicin 60 mg/m2 + cyclophosphamide 600 mg/m2 every 3 weeks for 4 cycles followed by paclitaxel 80 mg/m2 for 12 weeks | Carboplatin AUC2 every week | No | Neoadjuvant | Not described |
| INFORM | 2012 | Cisplatin 75 mg/m2 every 3 weeks for 4 cycles | Doxorubicin 60 mg/m2 + cyclophosphamide 600 mg/m2 every 2–3 weeks for 4 cycles | Cisplatin 75 mg/m2 every 3 weeks | No | Neoadjuvant | < 10% |
| I‐SPY2 | 2010 | Paclitaxel 80 mg/m2 weekly + veliparib 50 mg twice daily + carboplatin AUC6 every 3 weeks for 12 weeks followed by doxorubicin 60 mg/m2 + cyclophosphamide 600 mg/m2 every 2 or 3 weeks for 4 cycles | Paclitaxel 80 mg/m2 weekly for 12 weeks followed by doxorubicin 60 mg/m2 + cyclophosphamide 600 mg/m2 every 2 or 3 weeks for 4 cycles | Carboplatin AUC6 every 3 weeks | No | Neoadjuvant | < 5% |
| Li 2020 | 2011 | Paclitaxel 150 mg/m2 + carboplatin AUC3 every 2 weeks for 8 cycles | Epirubicin 80 mg/m2 and cyclophosphamide 600 mg/m2 every 2 weeks for 4 cycles followed by paclitaxel 175 mg/m2 every 2 weeks for 4 cycles | Carboplatin AUC3 every 2 weeks | No | Adjuvant | < 1% |
| Nasr 2015 | 2008 | 5‐fluorouracil 500 mg/m2 + epirubicin 100 mg/m2 + cyclophosphamide 500 mg/m2 every 3 weeks for 3 cycles then docetaxel 80 mg/m2 + carboplatin AUC5 every 3 weeks for 3 cycles, followed by postoperative radiotherapy, followed by cyclophosphamide 50 mg daily and methotrexate 2.5 mg twice daily on days 1, 2 of each week for 1 year | 5‐fluorouracil 500 mg/m2 + epirubicin 100 mg/m2 + cyclophosphamide 500 mg/m2 every 3 weeks for 3 cycles then docetaxel 80 mg/m2 every 3 weeks for 3 cycles | Carboplatin AUC5 every 3 weeks | No | Adjuvant | Not described |
| NeoCART | 2016 | Docetaxel 75 mg/m2 + carboplatin AUC6 every 3 weeks for 6 cycles | Epirubicin 90 mg/m2 + cyclophosphamide 600 mg/m2 every 3 weeks for 4 cycles followed by docetaxel 100 mg/m2 every 3 weeks for 4 cycles | Carboplatin AUC6 every 3 weeks | No | Neoadjuvant | < 1% |
| PATTERN | 2011 | Paclitaxel 80 mg/m2 + carboplatin AUC2 days 1, 8, 15, every 28 days for 6 cycles | Cyclophosphamide 500 mg/m2 + epirubicin 100 mg/m2 + fluorouracil 500 mg/m2 every 3 weeks for 3 cycles followed by docetaxel 100 mg/m2 every 3 weeks for 3 cycles | Carboplatin AUC2 every week (days 1, 8, 15 every 28 days) | No | Adjuvant | < 1% |
| TBCRC 030 | 2014 | Cisplatin 75 mg/m2 every 3 weeks for 4 cycles | Doxorubicin 60 mg/m2 + cyclophosphamide 600 mg/m2 every 2 weeks for 4 cycles | Cisplatin 75 mg/m2 every 3 weeks | No | Neoadjuvant | < 5% |
| Wu 2018 | 2014 | Lobaplatin 30 mg/m2 for 4 cycles + epirubicin 80 mg/m2 + docetaxel 75 mg/m2 every 3 weeks presurgery and 2 cycles postsurgery | Epirubicin 80 mg/m2 for 4 cycles + docetaxel 75 mg/m2 every 3 weeks presurgery and 2 cycles postsurgery | Lobaplatin 30 mg/m2 every 3 weeks | Yes | Both | < 10% |
| Zhang 2016 | 2006 | Paclitaxel 175 mg/m2 + carboplatin AUC5 every 3 weeks for 4–6 cycles | Epirubicin 75 mg/m2 + paclitaxel 175 mg/m2 every 3 weeks for 4–6 cycles | Carboplatin AUC5 every 3 weeks | No | Neoadjuvant | < 10% |
| Zhao 2014 | Not provided in translation | Paclitaxel 175 mg/m2 day 1, carboplatin AUC5 day 2, every 3 weeks for 2 cycles | Epirubicin 75 mg/m2 day 1, paclitaxel 175 mg/m2 day 2, every 3 weeks for 2 cycles | Carboplatin AUC5 every 3 weeks | No | Neoadjuvant | Not provided in translation |
| Zheng 2022 | 2009 | Docetaxel 75 mg/m2 or paclitaxel 175 mg/m2 + carboplatin AUC5 every 3 weeks for 6 cycles | Epirubicin 90 mg/m2 + cyclophosphamide 600 mg/m2 every 3 weeks for 4 cycles, followed by docetaxel 75 mg/m2 or paclitaxel 175 mg/m2 every 3 weeks for 4 cycles | Carboplatin AUC5 every 3 weeks | No | Adjuvant | < 1% |
AUC: area under the curve; IHC: immunohistochemistry.